alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2016111EN.01001901.xml

| 29.3.2016 | EN | Official Journal of the European Union | C 111/19 |
| --- | --- | --- | --- |

29.3.2016

EN

Official Journal of the European Union

C 111/19

---

Judgment of the General Court of 19 February 2016 — Ludwig-Bölkow-Systemtechnik v Commission

(Case T-53/14) (1)

1

((Arbitration clause - Sixth framework programme for research, technological development and demonstration activities - Reimbursement of a portion of the amounts paid and flat-rate compensation - No need to adjudicate in part - Costs eligible for EU funding - Penalty clause - Manifestly excessive character))

(2016/C 111/22)

Language of the case: German

Parties

Parties

Applicant: Ludwig-Bölkow-Systemtechnik GmbH (Ottobrunn, Germany) (represented by: initially, M. Núñez Müller and T. Becker, and, subsequently, M. Núñez Müller, lawyers)

Applicant:

Defendant: European Commission (represented by: T. Maxian Rusche and F. Moro, acting as Agents)

Defendant:

Re:

Re:

Application for a declaration, first, that the Commission is not entitled to require the applicant to reimburse advances paid under three contracts and, secondly, that the applicant is not required to pay flat-rate compensation to the Commission.

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Declares that there is no longer any need to adjudicate on the second and third heads of claim of the action; |
| --- | --- |

1.

Declares that there is no longer any need to adjudicate on the second and third heads of claim of the action;

| 2. | Declares that the sums payable as flat-rate compensation by Ludwig-Bölkow-Systemtechnik GmbH are to be reduced by an amount equivalent to 10 % of the advances to be reimbursed under the contracts concerning the projects HyWays, HyApproval and HarmonHy; |
| --- | --- |

2.

Declares that the sums payable as flat-rate compensation by Ludwig-Bölkow-Systemtechnik GmbH are to be reduced by an amount equivalent to 10 % of the advances to be reimbursed under the contracts concerning the projects HyWays, HyApproval and HarmonHy;

| 3. | Dismisses the action as to the remainder; |
| --- | --- |

3.

Dismisses the action as to the remainder;

| 4. | Orders Ludwig-Bölkow-Systemtechnik and the European Commission to bear their own respective costs. |
| --- | --- |

4.

Orders Ludwig-Bölkow-Systemtechnik and the European Commission to bear their own respective costs.

---

(1)  OJ C 129, 28.4.2014.

1

---
Editorial Note on Part 73
Editorial Note: Nomenclature changes to part 73 appear at 66 FR 66742, Dec. 27, 2001.

§ 73.125 Sodium copper chlorophyllin. ( a ) *Identity.* ( 1 ) The color additive sodium copper chlorophyllin is a green to black powder prepared from chlorophyll by saponification and replacement of magnesium by copper. Chlorophyll is extracted from alfalfa (*Medicago sativa*) using any one or a combination of the solvents acetone, ethanol, and hexane.
( 2 ) Color additive mixtures made with sodium copper chlorophyllin may contain only those diluents that are suitable and are listed in this subpart as safe for use in color additive mixtures for coloring foods.
( b ) *Specifications.* Sodium copper chlorophyllin shall conform to the following specifications and shall be free from impurities other than those named to the extent that such impurities may be avoided by good manufacturing practice: ( 1 ) Moisture, not more than 5.0 percent.
( 2 ) Solvent residues (acetone, ethanol, and hexane), not more than 50 parts per million, singly or, in combination.
( 3 ) Total copper, not less than 4 percent and not more than 6 percent.
( 4 ) Free copper, not more than 200 parts per million.
( 5 ) Lead (as Pb), not more than 10 parts per million.
( 6 ) Arsenic (as As), not more than 3 parts per million.
( 7 ) Mercury (as Hg), not more than 0.5 part per million.
( 8 ) Ratio of absorbance at 405 nanometers (nm) to absorbance at 630 nm, not less than 3.4 and not more than 3.9.
( 9 ) Total copper chlorophyllins, not less than 95 percent of the sample dried at 100 °C for 1 hour.
( c ) *Uses and restrictions.* Sodium copper chlorophyllin may be safely used to color citrus-based dry beverage mixes in an amount not exceeding 0.2 percent in the dry mix.
( d ) *Labeling requirements.* The label of the color additive and any mixtures prepared therefrom shall conform to the requirements of § 70.25 of this chapter.
( e ) *Exemption from certification.* Certification of this color additive is not necessary for the protection of the public health, and therefore batches thereof are exempt from the certification requirements of section 721(c) of the act.
[67 FR 35431, May 20, 2002]
§ 206.7 Exemptions. ( a ) The following classes of drug products are exempt from requirements of this part: ( 1 ) Drug products intended for use in a clinical investigation under section 505(i) of the act, but not including drugs distributed under a treatment IND under part 312 of this chapter or distributed as part of a nonconcurrently controlled study. Placebos intended for use in a clinical investigation are exempt from the requirements of this part if they are designed to copy the active drug products used in that investigation.
( 2 ) Drugs, other than reference listed drugs, intended for use in bioequivalence studies.
( 3 ) Drugs that are extemporaneously compounded by a licensed pharmacist, upon receipt of a valid prescription for an individual patient from a practitioner licensed by law to prescribe or administer drugs, to be used solely by the patient for whom they are prescribed.
( 4 ) Radiopharmaceutical drug products.
( b ) Exemption of drugs because of size or unique physical characteristics: ( 1 ) For a drug subject to premarket approval, FDA may provide an exemption from the requirements of § 206.10 upon a showing that the product's size, shape, texture, or other physical characteristics make imprinting technologically infeasible or impossible. ( i ) Exemption requests for products with approved applications shall be made in writing to the appropriate review division in the Center for Drug Evaluation and Research (CDER), Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266 or the Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Ave., Bldg. 71, Rm. G112, Silver Spring, MD 20993-0002. If FDA denies the request, the holder of the approved application will have 1 year after the date of an agency denial to imprint the drug product.
( ii ) Exemption requests for products that have not yet received approval shall be made in writing to the appropriate review division in CDER or CBER.
( 2 ) Any product not subject to premarket approval is exempt from the requirement of § 206.10 if, based on the product's size, shape, texture, or other physical characteristics, the manufacturer or distributor of the product is prepared to demonstrate that imprinting the dosage form is technologically infeasible or impossible.
( c ) For drugs that are administered solely in controlled health care settings and not provided to patients for self-administration, sponsors may submit requests for exemptions from the requirements of this rule. Controlled settings include physicians' offices and other health care facilities. Exemption requests should be submitted in writing to the appropriate review division in CDER or CBER.
[58 FR 47958, Sept. 13, 1993, as amended at 70 FR 14981, Mar. 24, 2005; 74 FR 13112, Mar. 26, 2009; 80 FR 18091, Apr. 3, 2015]
### IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 15

- 41174 Summary Calendar

UNITED STATES OF AMERICA , Plaintiff

- Appellee

v.
ANDRE DONNELL ROUTT , Defendant

- Appellant

Appeal from the United States District Court for the Eastern District of Texas USDC No. 1:94

- CR

- 12

Before KING, CLEMENT, and OWEN, Circuit Judges. PER CURIAM: * Andre Donnell Routt, federal prisoner # 60985

- 079, appeals the denial of his motion to reduce his sentence under 18 U.S.C. § 3582(c)(2) based on Amendment 782 to the Sentencing Guidelines. Routt contends th at he was
entitled to a two

- level reduction of hi s base offense level under Amendment
782 and that, as a result, his new base offense level would be 36.

* Pursuant to 5 TH C IR

. R. 47.5 , the court has determined that this opinion should not be published and is not precedent except under the limited circumstances se t forth in 5 TH C IR

. R. 47.5.4. United States Court of Appeals Fifth Circuit 

### FILED April 1, 2016 Lyle W. Cayce Clerk Case: 15-41174 Document: 00513448417 Page: 1 Date Filed: 04/01/2016No. 15

- 41174

2 The record confirms that Routt was ineligible for a sentence reduction under § 3582(c)(2) because Amendment 782 did not lower his base offense level. Routt fails to acknowledge that he was held responsible for 42.5 kilograms and four ounces of crack cocaine and 150 kilograms of powder cocaine. Under the

re troactive, amended version of U.S.S.G. § 2D1.1(c)( 1), which has now taken effect, Routt has a base offense level of 38 because he was responsible for the equivalent of more than 90,000 kilograms of marijuana. See § 2D1.1(c)(1) (2015 ). His specific offense level enhancements added six more levels

. Routt’s total offense level of 44 , together with a criminal history category of I V , results in a guidelines range of life imprisonment. See U.S.S.G. Ch. 5 , Pt. A. Because Amendment 782 d id not reduce Routt’s sentencing range, the district court properly found that he was ineligible for relief under § 3582(c)(2). See U.S.S.G. § 1B1.10(a)(2)(B) & comment. (n.1(A)); Dillon v. United States , 560 U.S. 817, 826 (2010). The judgment of the dis trict court is AFFIRMED. Case: 15-41174 Document: 00513448417 Page: 2 Date Filed: 04/01/2016
IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 12-31270

Summary Calendar

UNITED STATES OF AMERICA,

Plaintiff-Appellee

v.

DARRYL MOORE,

Defendant-Appellant

Appeal from the United States District Court

for the Eastern District of Louisiana

USDC No. 2:10-CR-331-1

Before DAVIS, SOUTHWICK and HIGGINSON, Circuit Judges.

PER CURIAM:*

The attorney appointed to represent Darryl Moore has moved for leave 

to withdraw and has filed a brief in accordance with Anders v. California, 386 

U.S. 738 (1967), and United States v. Flores, 632 F.3d 229 (5th Cir. 2011). 

Moore has filed a response. We have reviewed counsel’s brief and the relevant 

portions of the record reflected therein, as well as Moore’s response. We concur 

with counsel’s assessment that the appeal presents no nonfrivolous issue for 

* Pursuant to 5TH CIR. R. 47.5, the court has determined that this opinion should not 

be published and is not precedent except under the limited circumstances set forth in 5TH 

CIR. R. 47.5.4.

United States Court of Appeals

Fifth Circuit

FILED

March 11, 2014

Lyle W. Cayce

Clerk

 

 Case: 12-31270 Document: 00512557613 Page: 1 Date Filed: 03/11/2014
No. 12-31270

appellate review. Accordingly, counsel’s motion for leave to withdraw is 

GRANTED, counsel is excused from further responsibilities herein, and the 

APPEAL IS DISMISSED. See 5TH CIR. R. 42.2.

2

 Case: 12-31270 Document: 00512557613 Page: 2 Date Filed: 03/11/2014
§ 524.970 Flunixin. ( a ) *Specifications.* Each milliliter of solution contains 50 milligrams (mg) flunixin (equivalent to 83 mg flunixin meglumine).
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.286 of this chapter.
( d ) *Conditions of use* — ( 1 ) *Amount.* Apply only once at a dose of 3.3 mg flunixin per kg body weight (1.5 mg/lb; 3 mL per 100 lbs) topically in a narrow strip along the dorsal midline from the withers to the tailhead.
( 2 ) *Indications for use.* For the control of pyrexia associated with bovine respiratory disease and acute bovine mastitis, and the control of pain associated with foot rot in beef cattle 2 months of age and older and dairy cattle.
( 3 ) *Limitations.* Not for use in beef and dairy bulls intended for breeding over 1 year of age. Milk that has been taken during treatment and for 48 hours after treatment must not be used for human consumption. Cattle must not be slaughtered for human consumption within 8 days of treatment. Not for use in replacement dairy heifers 20 months of age or older or dry dairy cows; use in these cattle may cause drug residues in calves born to these cows or heifers. Not for use in beef calves less than 2 months of age, dairy calves, and veal calves. A withdrawal period has not been established for this product in pre-ruminating calves. Approved only as a single topical dose in cattle. Repeated treatments may result in violative residues in milk or in edible tissues. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[83 FR 13635, Mar. 30, 2018, as amended at 88 FR 16549, Mar. 20, 2023]
§ 516.36 Insufficient quantities of MUMS-designated drugs. ( a ) Under section 573 of the act, whenever FDA has reason to believe that sufficient quantities of a conditionally-approved or approved, MUMS-designated drug to meet the needs for which the drug was designated cannot be assured by the sponsor, FDA will so notify the sponsor of this possible insufficiency and will offer the sponsor the following options, one of which must be exercised by a time that FDA specifies: ( 1 ) Provide FDA information and data regarding how the sponsor can assure the availability of sufficient quantities of the MUMS-designated drug within a reasonable time to meet the needs for which the drug was designated; or
( 2 ) Provide FDA in writing the sponsor's consent for the conditional approval or approval of other applications for the same drug before the expiration of the 7-year period of exclusive marketing rights.
( b ) If, within the time that FDA specifies, the sponsor fails to consent to the conditional approval or approval of other applications and if FDA finds that the sponsor has not shown that it can assure the availability of sufficient quantities of the MUMS-designated drug to meet the needs for which the drug was designated, FDA will issue a written order terminating designation of the MUMS drug and the associated exclusive marketing rights. This order will state FDA's findings and conclusions and will constitute final agency action. An order terminating designation and associated exclusive marketing rights may issue whether or not there are other sponsors that can assure the availability of alternative sources of supply. Such an order will not withdraw the conditional approval or approval of an application. Once terminated under this section, neither designation, nor exclusive marketing rights may be reinstated.
EXHIBIT 32.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

 

This certification is provided pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and accompanies the Quarterly Report on Form 10-Q (the “Form 10-Q”) for the quarter ended June 30, 2009 of Crimson Exploration Inc. (the “Issuer”). The undersigned hereby certifies that the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the            Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Issuer. 

| Date:

  | August 12, 2009

  |   |
|---------------|-------------------------|--------|
|          | /s/ E. Joseph Grady     |   |
| Name:         | E. Joseph Grady         |   |
| Title:        | Chief Financial Officer |   |
|          |                    |   |
|          |                    |   |

 

A signed original of this written statement required by Section 906 has been provided to the Issuer and will be furnished to the Securities and Exchange Commission, or its staff, upon request.
§ 582.5191 Calcium carbonate. ( a ) *Product.* Calcium carbonate.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 601.5 Revocation of license. ( a ) A biologics license shall be revoked upon application of the manufacturer giving notice of intention to discontinue the manufacture of all products manufactured under such license or to discontinue the manufacture of a particular product for which a license is held and waiving an opportunity for a hearing on the matter.
( b ) ( 1 ) The Commissioner shall notify the licensed manufacturer of the intention to revoke the biologics license, setting forth the grounds for, and offering an opportunity for a hearing on the proposed revocation if the Commissioner finds any of the following: ( i ) Authorized Food and Drug Administration employees after reasonable efforts have been unable to gain access to an establishment or a location for the purpose of carrying out the inspection required under § 600.21 of this chapter,
( ii ) Manufacturing of products or of a product has been discontinued to an extent that a meaningful inspection or evaluation cannot be made,
( iii ) The manufacturer has failed to report a change as required by § 601.12 of this chapter,
( iv ) The establishment or any location thereof, or the product for which the license has been issued, fails to conform to the applicable standards established in the license and in this chapter designed to ensure the continued safety, purity, and potency of the manufactured product,
( v ) The establishment or the manufacturing methods have been so changed as to require a new showing that the establishment or product meets the requirements established in this chapter in order to protect the public health, or
( vi ) The licensed product is not safe and effective for all of its intended uses or is misbranded with respect to any such use.
( 2 ) Except as provided in § 601.6 of this chapter, or in cases involving willfulness, the notification required in this paragraph shall provide a reasonable period for the licensed manufacturer to demonstrate or achieve compliance with the requirements of this chapter, before proceedings will be instituted for the revocation of the license. If compliance is not demonstrated or achieved and the licensed manufacturer does not waive the opportunity for a hearing, the Commissioner shall issue a notice of opportunity for hearing on the matter under § 12.21(b) of this chapter.
[64 FR 56451, Oct. 20, 1999]
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of the Interior

###### Bureau of Land Management

          - [LLORW00000 L16100000.DO0000.WBSLXSS073H0000; GP10-0139]

# AGENCY:

Bureau of Land Management, Interior.

# ACTION:

Notice of public meeting.

# SUMMARY:

In accordance with the Federal Land Policy and Management Act of 1976 and the Federal Advisory Committee Act of 1972, the U.S. Department of the Interior, Bureau of Land Management (BLM) Eastern Washington Resource Advisory Council (EWRAC) will meet as indicated below.

# DATES:

Meeting will take place on March 25, 2010, from 10 a.m. to 2 p.m.

# ADDRESSES:

The meeting will be held at The Potato Commission, 108 S. Interlake Rd., Moses Lake, Washington 98837-2950.

# FOR FURTHER INFORMATION CONTACT:

BLM Spokane District, 1103 N. Fancher Rd., Spokane Valley, WA 99212, or call (509) 536-1200.

# SUPPLEMENTARY INFORMATION:

The meeting will be open to the public. It will begin at 10 a.m. and end at 2 p.m. on March 25. Members of the public will have an opportunity to address the EWRAC at 10 a.m. Discussion will focus on the Spokane and San Juan Islands Resource Management Plan.

Robert B. Towne,

Spokane District Manager.

[FR Doc. 2010-4224 Filed 3-1-10; 8:45 am]

BILLING CODE 4310-33-P
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7549 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7549

 To amend title 38, United States Code, to provide for the termination 
  of a certain educational assistance program, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 5, 2024

  Mr. Mrvan introduced the following bill; which was referred to the 
                     Committee on Veterans' Affairs

_______________________________________________________________________

                                 A BILL

 
 To amend title 38, United States Code, to provide for the termination 
  of a certain educational assistance program, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Gold Star Family Education Parity 
Act''.

SEC. 2. TERMINATION OF AUTHORITY FOR CERTAIN EDUCATIONAL ASSISTANCE 
              PROGRAM.

    (a) Survivors' and Dependents' Educational Assistance.--Chapter 35 
of title 38, United States Code, is amended by adding at the end the 
following new subchapter:

                     ``SUBCHAPTER VIII--TERMINATION

``Sec. 3571. Termination of authority
    ``(a) In General.--The authority to provide educational assistance 
under this chapter shall terminate on August 1, 2028.
    ``(b) Eligibility for Post-9/11 Educational Assistance.--An 
individual who is no longer eligible for educational assistance under 
this chapter pursuant to subsection (a) shall be entitled to 
educational assistance under chapter 33 of this title in the same 
manner as if the individual had elected to receive educational 
assistance under section 3327 of this title, notwithstanding the 
restrictions on crediting service under section 3322(h)(1) of this 
title, but subject to the limitations under section 3327(d)(2) of this 
title.''.
    (b) Clerical Amendment.--The table of sections at the beginning of 
such chapter is amended by adding at the end the following:

                      ``subchapter viii-termination

``3571. Termination of authority.''.
                                 <all>
```